Bioinformatics in translational drug discovery

Abstract

Bioinformatics approaches are becoming ever more essential in translational drug discovery both in academia and within the pharmaceutical industry. Computational exploitation of the increasing volumes of data generated during all phases of drug discovery is enabling key challenges of the process to be addressed. Here, we highlight some of the areas in which bioinformatics resources and methods are being developed to support the drug discovery pipeline. These include the creation of large data warehouses, bioinformatics algorithms to analyse ‘big data’ that identify novel drug targets and/or biomarkers, programs to assess the tractability of targets, and prediction of repositioning opportunities that use licensed drugs to treat additional indications.

Metformin coordinates osteoblast/osteoclast differentiation associated with ischemic osteonecrosis

“…This has many advantages, such as no need to test toxicity or evaluate pharmacokinetics [9]. These advantages can considerably reduce the cost and time to develop new drugs, leading to improved success rates [10]. In this study, we adapted the drug repositioning concept to identify candidate drugs to promote differentiation of osteoblast-like cells by inducing Ang1 expression.…”

High-dimensionality Data Analysis of Pharmacological Systems Associated with Complex Diseases

“…The routine use of H-D data in pharmacological settings to facilitate appropriate matching of drug mechanisms to disease signatures allows scientists to begin to effectively exploit the multidimensional nature of biologic factors (e.g., transcript, metabolite, and especially protein) activity. The complex and dynamic interactions between these multiple entities during therapeutic interventions further increases the complexity of drug efficacy profiles (Maudsley et al, 2015(Maudsley et al, , 2016Bradley and Tobin, 2016;Besserer-Offroy et al, 2017;Wooller et al, 2017).…”

Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson’s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer

“…With the ever increasing pace of research, including in vitro and in vivo screening systems, advances in virtual drug modelling and bioinformatics approaches, the number of suitable drug candidates for clinical evaluation as potential disease modifying therapies is on the rise [5][6][7][8].…”